Risk factors for de novo hepatitis B infection in pediatric living donor liver transplantation

Table 1 Characteristics of children with de novo hepatitis B infection after liver transplantation

	Pre-operation data (serum)			Allograft			De novo HBV infection				HBV status follow-up
No.	HBsAb (IU/mL)	HBcAb (IU/mL)	HBVDNA (IU/mL)	HBsAb (IU/mL)	HBcAb (IU/mL)	HBVDNA/cccDNA (copies/cell)	Time after LT (mo)	HBsAg (IU/mL)	Serum HBVDNA (IU/mL)	Liver enzymes	HBsAb (IU/mL)	Serum HBVDNA (IU/mL)	Liver enzymes	Follow-up (mo)
1	< 2	1.04	< 100	251.8	0.010	2.57/0.08	25.4	1348	1.62 × E8	N	4745	1.62 × E8	N	35.3
2	< 2	1.36	< 100	462.4	0.007	Neg/neg	10.6	164.9	1.12 × E2	AN	5791	1.62 × E8	N	17.0
3	< 2	0.98	< 100	262.5	0.339	1.50/0.09	12	3608	2.90 × E9	N	3608	2.9 × E9	N	16.8
4	164.4	0.03	< 100	< 2	0.007	12.4/0.15	3.4	746.1	7.14 × E8	AN	1866	7.14 × E8	AN	4.0
5	31.4	0.23	< 100	210.0	0.009	3.61/0.09	8.7	2345	1.46 × E8	N	3213	1.46 × E8	N	15.2

HBsAb: Hepatitis B surface antibody; HBcAb: Hepatitis B core antibody; HBV: Hepatitis B virus; cccDNA: Covalently closed circular DNA; LT: Liver transplantation; N: Normal; AN: Abnormal.

Table 2 Demographic and clinical characteristics of children according to donor hepatitis B core antibody status

Characteristic	HBcAb(+) donor(n = 16)	HBcAb(-) donor(n = 14)	P value
Donors
Gender (n, M/F)	7/9	9/5	0.261
Age (yr)	35 (20-55)	32 (22-54)	0.884
HBsAb (+/-)	14/2	9/5	0.134
Recipients
Age (mo)	11 (7-43)	12 (6-57)	0.787
Gender (n, M/F)	9/7	8/6	0.981
PELD score	16 ± 3	17 ± 4	0.378
Preoperative HBcAb (n, +/-)	11/5	5/9	0.070
Preoperative HBsAb (n, +/-)	11/5	7/7	0.300
Preoperative HBsAb/HBcAb (n, +/-)	9/7	3/11	0.052
Blood transfusion
RBC (mL)	502 ± 284	534 ± 224	0.379
FFP (mL)	404 ± 177	424 ± 210	0.753
Dose of corticosteroid/body weight (mg/kg)	44 ± 7	42 ± 8	0.359
Trough value of TAC
First 3 mo (ng/mL)	8.1 ± 5.6	7.8 ± 4.6	0.789
3 mo later (ng/mL)	6.7 ± 3.2	6.4 ± 2.3	0.661
Follow-up (mo)	15 (4-40)	16 (14-30)	0.228
De novo HBV infection (n, +/-)	5/11	0/14	0.022

M/F: Male/female; HBV: Hepatitis B virus; PELD: Pediatric model of end-stage liver disease; HBcAb: Hepatitis B core antibody; HBsAb: Hepatitis B surface antibody; RBC: Red blood cell; FFP: Fresh frozen plasma.

Table 3 Demographics and clinical characteristics of children with hepatitis B core antibody-positive allografts according to de novo hepatitis B virus infection status after living donor liver transplantation

Characteristics	De novo HBV infection (n = 5)	De novo HBV infection-free (n = 11)	P value
Donors
Age (yr)	38 (22-55)	30 (27-50)	0.223
Gender (n, M/F)	3/2	5/6	0.590
HBsAb (n, +/-)	4/1	10/1	0.541
Intrahepatic HBV DNA (n, +/-)	4/1	3/8	0.043
Recipients
Age (mo)	14 (10-18)	10 (8-43)	0.113
Gender (n, M/F)	2/3	6/5	0.590
PELD score	17 ± 3	17 ± 4	0.469
Preoperative HBcAb (n, +/-)	3/2	3/8	0.610
Preoperative HBsAb (n, +/-)	2/3	2/9	0.350
Preoperative ant-HBs/HBcAb (n, +/-)	2/3	7/4	0.377
Blood transfusion
RBC (mL)	420 ± 220	540 ± 172	0.216
FFP (mL)	416 ± 184	400 ± 183	0.908
Dose of prednisone/bodyweight (mg/kg)	46 ± 6	43 ± 8	0.318
Follow-up (mo)	17 (4-35)	14 (12-40)	0.356

M/F: Male/female; HBV: Hepatitis B virus; PELD: Pediatric model of end-stage liver disease; HBcAb: Hepatitis B core antibody; HBsAb: Hepatitis B surface antibody; RBC: Red blood cell; FFP: Fresh frozen plasma.